The nation of Zimbabwe has rejected a substantial US healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years due to Washington's demand for confidential biological samples.
This rejection was revealed after a official document from December was disclosed, indicating that President Emmerson Mnangagwa felt the arrangement was "skewed".
A government spokesperson later explained that the United States was demanding access to biological samples for research and commercial purposes while refused to share the benefits from any future vaccines.
"We will now turn to the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged continued talks to reach a deal suitable to both sides so the country's vital HIV treatment initiative can continue.
Wider Implications
This rejection follows a similar situation in Kenya, where a high court halted a related health funding agreement following legal challenges were raised about the safety of Kenyans' health data.
After returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump stated its expenditure was "inefficient" and his government was seeking government-to-government agreements to enhance openness and accountability.
Based on reports, 16 nations in Africa have so far agreed to these new health pacts, representing more than $18.3bn in committed funds.
Specifics of the Declined Agreement
The funds for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation might have yielded immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on antiretroviral therapy through American-funded programmes," the Ambassador said.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Zimbabwe was being asked to surrender its genetic material and health information for a long time, without any corresponding assurance of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might result from that shared data," he stated.
"Effectively, our nation would provide the raw materials for scientific discovery with no certainty that the final treatments would be available to our people if a future pandemic arise."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were undermining frameworks previously set up via the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to manage future global health emergencies.
"This framework is intended to guarantee that when a nation provides its data, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to develop them."
The government's concerns over the US deal "must not be interpreted as anti-American sentiment," he added.
"We are open to further dialogue with our US partners on how subsequent co-operation might be structured in a way that respects the independence and interests of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the official position, but recommended that talks must proceed since a large portion of the country's HIV programmes depended on foreign aid.
"In cases where specific concerns exist, such as those relating to information security or implementation frameworks, these can often be resolved through technical clarification and mutually agreed protections," the group said.
The halted deal underscores the complex debate between receiving vital foreign assistance and protecting a country's data in an increasingly interconnected world.